Stay updated on Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial
Sign up to get notified when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.

Latest updates to the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedUpdated version to v3.2.0 and added a government operating-status notice for NIH Clinical Center, directing users to cc.nih.gov and opm.gov.SummaryDifference3%

- Check27 days agoChange DetectedReplaces/phases out pharmaceutical-solution categories with broader chemical categories and updates the version to v3.1.0; several prior solution-related terms are removed.SummaryDifference0.9%

- Check42 days agoChange DetectedThe page revision is updated from v3.0.1 to v3.0.2, and the Back to Top element has been removed. There are no changes to core content, pricing, stock, or time-sensitive information.SummaryDifference0.2%

- Check49 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%

- Check56 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as new content related to drug safety and various types of solutions. The previous location details and revision information have been removed.SummaryDifference1%

- Check70 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12, indicating a revision in the content.SummaryDifference0.1%

Stay in the know with updates to Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.